Cargando…

Therapeutic vaccination using HPV 16 E7 to eradicate CIN3

Detalles Bibliográficos
Autor principal:	Tewari, Krishnansu S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779628/ https://www.ncbi.nlm.nih.gov/pubmed/31576704 http://dx.doi.org/10.3802/jgo.2019.30.e119

Ejemplares similares

Usefulness of E7 mRNA in HPV16-Positive Women to Predict the Risk of Progression to HSIL/CIN2+
por: Martí, Cristina, et al.
Publicado: (2021)

Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients
por: Kim, Tae Jin, et al.
Publicado: (2014)

HPV58 E7 Protein Expression Profile in Cervical Cancer and CIN with Immunohistochemistry
por: Zheng, Qiaoli, et al.
Publicado: (2021)

Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1
por: Einstein, Mark H., et al.
Publicado: (2023)

Fusion of CTLA-4 with HPV16 E7 and E6 Enhanced the Potency of Therapeutic HPV DNA Vaccine
por: Gan, Lili, et al.
Publicado: (2014)

Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years
por: Paaso, Anna, et al.
Publicado: (2015)

Progression of CIN1/LSIL HPV Persistent of the Cervix: Actual Progression or CIN3 Coexistence
por: Bruno, Maria Teresa, et al.
Publicado: (2021)

Enhanced HPV16 E6/E7(+) tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides
por: Stegmann, Toon, et al.
Publicado: (2023)

Efficacy and safety of therapeutic HPV vaccines to treat CIN 2/CIN 3 lesions: a systematic review and meta-analysis of phase II/III clinical trials
por: Ibrahim Khalil, Ahmadaye, et al.
Publicado: (2023)

Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial
por: Karimi-Zarchi, Mojgan, et al.
Publicado: (2020)

Chimeric Infectious Bursal Disease Virus-Like Particles as Potent Vaccines for Eradication of Established HPV-16 E7–Dependent Tumors
por: Martin Caballero, Juan, et al.
Publicado: (2012)

HPV16 E6/E7 -based mRNA vaccine is therapeutic in mice bearing aggressive HPV-positive lesions
por: Zhou, Kun, et al.
Publicado: (2023)

Bayesian analysis of baseline risk of CIN2 and ≥CIN3 by HPV genotype in a European referral cohort
por: Bonde, Jesper, et al.
Publicado: (2019)

A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection
por: Monroy-García, Alberto, et al.
Publicado: (2011)

Conservative management of CIN2 p16 positive lesions in women with multiple HPV infection
por: Bruno, Maria Teresa, et al.
Publicado: (2020)

Brucella abortus RB51 lipopolysaccharide influence as an adjuvant on the therapeutic efficacy of HPV16 L1 and HPV16 E7 DNA vaccines
por: Shirmohammadi, Masoumeh, et al.
Publicado: (2021)

Consistent condom use increases spontaneous regression in high-risk non-HPV16 but not in HPV16 CIN2-3 lesions, a prospective population-based cohort study
por: Munk, Ane Cecilie, et al.
Publicado: (2012)

Should adjuvant chemotherapy be formally studied among patients found to have pelvic lymph node metastases following radical hysterectomy with lymphadenectomy for early-stage cervical cancer?
por: Bujnak, Alyssa C., et al.
Publicado: (2021)

HPV16 variant analysis in primary and recurrent CIN2/3 lesions demonstrates presence of the same consensus variant
por: van der Weele, Pascal, et al.
Publicado: (2019)

Evaluating HPV‐negative CIN2+ in the ATHENA trial
por: Petry, Karl Ulrich, et al.
Publicado: (2016)

A Non-oncogenic HPV 16 E6/E7 Vaccine Enhances Treatment of HPV Expressing Tumors
por: Wieking, Bryant G., et al.
Publicado: (2012)

The Accuracy of p16/Ki-67 and HPV Test in the Detection of CIN2/3 in Women Diagnosed with ASC-US or LSIL
por: Possati-Resende, Júlio C., et al.
Publicado: (2015)

Up to your NEK2 in CIN
por: Seachrist, Darcie D., et al.
Publicado: (2021)

Temporal changes in the vaginal microbiota in self-samples and its association with persistent HPV16 infection and CIN2+
por: Berggrund, Malin, et al.
Publicado: (2020)

Control of Spontaneous HPV16 E6/E7 Expressing Oral Cancer in HLA-A2 (AAD) Transgenic Mice with Therapeutic HPV DNA Vaccine
por: Tseng, Ssu-Hsueh, et al.
Publicado: (2021)

Triage of HPV-positive women in Norway using cytology, HPV16/18 genotyping and HPV persistence
por: Arbyn, Marc, et al.
Publicado: (2020)

Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach
por: Jindra, Christoph, et al.
Publicado: (2015)

HPV E6/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia (CIN2+): a systematic review
por: Derbie, Awoke, et al.
Publicado: (2020)

Impact of HPV mRNA types 16, 18, 45 detection on the risk of CIN3+ in young women with normal cervical cytology
por: Al-Shibli, Khalid, et al.
Publicado: (2022)

Enhancement of potent immune responses to HPV16 E7 antigen by using different vaccine modalities
por: Bolhassani, Azam, et al.
Publicado: (2011)

Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16(+) cancer
por: Salomon, Nadja, et al.
Publicado: (2021)

Correction: Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach
por: Jindra, Christoph, et al.
Publicado: (2015)

HPV-Testing in Follow-up of Patients Treated for CIN2+ Lesions
por: Mariani, Luciano, et al.
Publicado: (2016)

HPV 16 E7 alters translesion synthesis signaling
por: Wendel, Sebastian O., et al.
Publicado: (2022)

Predictive Testing of Early CIN Behaviour by Molecular Biomarkers
por: Baak, Jan P. A., et al.
Publicado: (2005)

E6/E7 mRNA testing for human papilloma virus-induced high-grade cervical intraepithelial disease (CIN2/CIN3): a promising perspective
por: Origoni, Massimo, et al.
Publicado: (2015)

E2/E6 ratio and L1 immunoreactivity as biomarkers to determine HPV16-positive high-grade squamous intraepithelial lesions (CIN2 and 3) and cervical squamous cell carcinoma
por: Choi, Youn-Jin, et al.
Publicado: (2018)

Long-term CIN3+ risk in women with abnormal cytology; role of hrHPV testing
por: Kocken, M, et al.
Publicado: (2012)

HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test
por: Polman, Nicole J, et al.
Publicado: (2017)

A novel HPV16 E7-affitoxin for targeted therapy of HPV16-induced human cervical cancer
por: Jiang, Pengfei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0265i81tj0fukv5rqkje4lpp8n